Since its inception in 1984 the principal goal of the TIMI Study Group has been to conduct high quality clinical trials that enhance the care of patients with coronary artery disease. TIMI has been involved in a wide array of phase 1 to phase 4 trials as well as registries. These have ranged in size from less than 30 to more than 300,000 subjects. The interventions studied include fibrinolytic, antithrombotic, anti-platelet, anti-ischemic and lipid lowering agents as well as percutaneous coronary intervention. In addition, the TIMI Study Group has used its growing database of clinical findings, biomarkers, and genetic tests to enhance the understanding of coronary artery disease. An important corollary goal has been to train the next generation of clinical investigators. TIMI is especially proud of those trainees who have assumed leadership positions in leading institutions around the world.